［1］Global Burden of Disease 2019 Cancer Collaboration,KOCARNIK JM,COMPTON K,et al.Cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life years for 29 cancer groups from 2010 to 2019：A systematic analysis for the global burden of disease study 2019［J］.JAMA Oncol,2022,8(3):420-444.
［2］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［3］QIU H,CAO S,XU R.Cancer incidence,mortality,and burden in China：A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020［J］.Cancer Commun(Lond),2021,41(10):1037-1048.
［4］赖闺娥,林志琴,刘凤恩.新辅助化疗后乳腺癌患者乳房病理完全缓解及腋窝淋巴结非病理完全缓解相关临床研究［J］.赣南医学院学报,2023,43(11):1097-1101.
LAI GE,LIN ZQ,LIU FE.Clinical study on breast pCR and axillary lymph node non-pCR in patients withbreast cancer after neoadjuvant chemotherapy［J］.Journal of Gan Nan Medical University,2023,43(11):1097-1101.
［5］CORTAZAR P,ZHANG L,UNTCH M,et al.Pathological complete response and long-term clinical benefit in breast cancer：The CTNeoBC pooled analysis［J］.Lancet,2014,384(9938):164-172.
［6］SPRING LM,FELL G,ARFE A,et al.Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival：A comprehensive Meta-analysis［J］.Clin Cancer Res,2020,26(12):2838-2848.
［7］CAUDLE AS,GONZALEZ-ANGULO AM,HUNT KK,et al.Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer［J］.J Clin Oncol,2010,28(11):1821-1828.
［8］PEROU CM,SORLIE T,EISEN MB,et al.Molecular portraits of human breast tumours［J］.Nature,2000,406(6797):747-752.
［9］HAQUE W,VERMA V,HATCH S,et al.Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy［J］.Breast Cancer Res Treat,2018,170(3):559-567.
［10］DAVEY MG,RYAN EJ,FOLAN PJ,et al.The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer［J］.BJS Open,2021,5(3):zrab040.
［11］DAVEY MG,RYAN EJ,MCANENA PF,et al.Disease recurrence and oncological outcome of patients treated surgically with curative intent for estrogen receptor positive,lymph node negative breast cancer［J］.Surg Oncol,2021,37:101531.
［12］鞠仙莉,袁修学,阎红琳,等.乳腺癌新辅助化疗疗效预测指标的研究进展［J］.中国组织化学与细胞化学杂志,2023,32(03):323-327.
JU XL,YUAN XX,YAN HL,et al.Research progress on prognostic indicators of neoadjuvant chemotherapy for breastcancer［J］.Chinese Journal of Histochemistry and Cytochemistry,2023,32(03):323-327.
［13］JOHNSTON S,PUHALLA S,WHEATLEY D,et al.Randomized phase Ⅱ study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer：PALLET trial［J］.J Clin Oncol,2019,37(3):178-189.
［14］HAMMOND ME,HAYES DF,DOWSETT M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer［J］.J Clin Oncol,2010,28(16):2784-2795.
［15］PAN Y,YUAN Y,LIU G,et al.p53 and Ki-67 as prognostic markers in triple-negative breast cancer patients［J］.PLoS One,2017,12(2):e0172324.
［16］GOLDHIRSCH A,WINER EP,COATES AS,et al.Personalizing the treatment of women with early breast cancer：Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013［J］.Ann Oncol,2013,24(9):2206-2223.
［17］王晓敏,彭璐珊,王潇潇,等.不同HER-2表达水平乳腺癌患者新辅助化疗疗效与生存分析［J］.中国普通外科杂志,2023,32(05):739-751.
WANG XM,PENG LS,WANG XX,et al.Analysis of the efficacy and survival outcomes of neoadjuvant chemotherapy in breast cancer patients with different HER-2 expression levels［J］.China Journal of General Surgery,2023,32(05):739-751.
［18］卢宇博,李咸君,张国强.影响乳腺癌新辅助化疗后病理完全缓解的临床因素分析［J］.现代肿瘤医学,2020,28(21):3737-3740.
LU YB,LI XJ,ZHANG GQ.Analysisof clinical factors influencing pCR of neoadjuvant chemotherapy for breast cancer［J］.Modern Oncology,2020,28(21):3737-3740.
［19］邓丁梅,叶娴,温润耀,等.ER、PR以及Ki-67状态与乳腺癌新辅助化疗疗效的相关性［J］.分子诊断与治疗杂志,2021,13(01):83-86,90.
DENG DM,YE X,WEN RY,et al.Correlation of ER，PR，and Ki-67 status with the efficacy of neoadjuvant chemotherapyfor breast cancer［J］.J Mol Diagn Ther,2021,13(01):83-86,90.
［20］LI Z,WEI H,LI S,et al.The role of progesterone receptors in breast cancer［J］.Drug Des Devel Ther,2022,16:305-314.
［21］GUAN D,JIE Q,WU Y,et al.Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive,human epidermal growth factor receptor-2-negative breast cancer：A multicenter,retrospective study in China［J］.World J Surg Oncol,2022,20(1):326.
［22］马金平,王海波,张剑,等.雌激素受体阳性HER2阴性乳腺癌新辅助化疗反应的影响因素分析［J］.中国妇幼健康研究,2023,34(09):68-74.
MA JP,WANG HB,ZHANG J,et al.Analysis of influencing factors of neoadjuvant chemotherapy response in estrogen receptor positive HER2 negative breast cancer［J］.Chinese Maternal and Child Health Research,2023,34(09):68-74.
［23］徐玲玉,江勇,杨澜.Her-2阴性乳腺癌中激素受体、Ki-67、P53的表达与蒽环类新辅助化疗疗效的关系［J］.河南外科学杂志,2014,20(04):5-7.
XU LY,JIANG Y,YANG L.Hormone receptors,Ki-67,P53 expression in Her-2 negative breast cancer and its relationship with neoadjuvant anthracycline-based chemotherapy in breast cancer［J］.Henan J Surgery,2014,20(04):5-7.
［24］王若曦,吉芃,龚悦,等.HER-2低表达乳腺癌新辅助化疗效果及其预后特征：一项单中心回顾性研究［J］.中国癌症杂志,2023,33(07):686-692.
WANG RX,JI P,GONG Y,et al.Effect and prognostic characteristics of neoadjuvant chemotherapy for breast cancer with low expression of HER-2:A single-center retrospective study［J］.Chin J Cancer,2023,33(07):686-692.
［25］刘运麟,彭厚坤,罗朝朗,等.老年乳腺癌新辅助化疗前后Her-2、ER和PR表达变化及其与患者预后的关系［J］.中国老年学杂志,2023,43(16):3902-3905.
LIU YL,PENG HK,LUO CL,et al.The changes of Her-2,ER and PR expression before and after neoadjuvant chemotherapy in elderly breast cancer and their relationship with the prognosis of patients［J］.Chinese Journal of Gerontology,2023,43(16):3902-3905.
［26］姬瑶,刘君,杨艳芳,等.158例乳腺癌新辅助化疗疗效与Ki-67截断值的相关分析［J］.中国肿瘤临床,2017,44(11):547-551.
JI Y,LIU J,YANG YF,et al.Correlation analysis between the efficacy of neoadjuvant chemotherapy and Ki-67 cutoff value in 158 cases of breast cancer［J］.China of Oncology,2017,44(11)：547-551.
［27］BAHRIN NWS,MATUSIN SNI,MUSTAPA A,et al.Exploring the effectiveness of molecular subtypes,biomarkers,and genetic variations as first-line treatment predictors in Asian breast cancer patients:A systematic review and meta-analysis［J］.Syst Rev,2024,13(1):100.
［28］YANG L,YE F,BAO L,et al.Somatic alterations of TP53,ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers［J］.Cancer Sci,2019,110(4):1389-1400.
［29］BI Z,LIU J,CHEN P,et al.Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla［J］.Breast Cancer,2019,26(3):373-377.
［30］唐铃丰,舒秀洁,严萍,等.雌激素受体阳性型乳腺癌新辅助化疗效果的影响因素及疗效预测［J］.第三军医大学学报,2020,42(23):2341-2349.
TANG LF，SHU XJ，YAN P, et al.Influencing factors and efficacy prediction of neoadjuvant chemotherapy for ER positive breast cancer［J］.Journal of Army Medical University,2020,42(23):2341-2349.
［31］丁红云,陆红梅,黄丽.乳腺癌新辅助化疗疗效预测模型的建立及其影响因素［J］.临床与病理杂志,2023,43(03):436-443.
DING HY,LU HM,HUANG L.Establishment of a model for pedicting the efficacy of NAC in breast cancer and its influencing factors［J］.J Clin and Pathology,2023,43(03):436-443.
［32］顾依涵,毛晓韵.乳腺癌新辅助化疗疗效评估［J］.中华肿瘤防治杂志,2024,31(02):118-124.
GU YH,MAO XY.Evaluation of the effectiveness of NAC in breast cancer［J］.Chinese Journal of Cancer Prevention and Treatment,2024,31(02)：118-124
［33］YERUSHALMI R,WOODS R,RAVDIN PM,et al.Ki-67 in breast cancer：Prognostic and predictive potential［J］.Lancet Oncol,2010,11(2):174-183.
［34］马海明,刘涛,刘晓康,等.乳腺癌组织Ki-67和HER-2及PHH3表达与新辅助化疗疗效相关性分析［J］.中华肿瘤防治杂志,2018,25(10):709-712.
MA HM,LIU T,LIU XK,et al.Correlation between the expression of Ki-67,HER-2 and PHH3 in breast cancer tissues and the efficacy of neoadjuvant chemotherapy［J］.Chin J Cancer Prevention and Treatment,2018,25(10):709-712.
［35］桑蝶,王佳玉,袁芃,等.Ki-67与乳腺癌临床病理特征及NAC疗效的相关性［J］.癌症进展,2015,13(03):291-297.
SANG D,WANG JY,YUAN P,et al.Correlation of Ki-67 with clinicopathological characteristics and efficacy of NAC in breast cancer［J］.Cancer Progress,2015,13(03):291-297.
［36］FASCHING PA,HEUSINGER K,HAEBERLE L,et al.Ki-67,chemotherapy response,and prognosis in breast cancer patients receiving neoadjuvant treatment［J］.BMC Cancer,2011,11:486.
［37］SCHOLZEN T,GERDES J.The Ki-67 protein：From the known and the unknown［J］.J Cell Physiol,2000,182(3):311-322.